Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R01HD082148 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Michigan Department of Health and Human Services | OTHER |
| Case Western Reserve University | OTHER |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NIH |
Not provided
Not provided
Not provided
Not provided
Obtaining adequate informed consent from potential research participants is a significant challenge for biobank-dependent research. To maintain public trust and support, it is important to establish an informed decision-making process for the collection and use of biospecimens collected within clinical settings. For the majority of all infants born in the US, residual dried blood biospecimens are generated after newborn screening is completed. Some programs choose to store these specimens for several uses including biomedical research. Identifying ways to improve comprehension about broad consent for future biobank-dependent research is a national priority. Specific Aim 1: Identify the key information items necessary to make an informed decision about broad consent for the retention and future research use of residual biospecimens. Methods include focus groups with new parents to determine key information elements relevant to consent for use of residual biospecimens within the Michigan BioTrust. Additional meetings with IRB personnel within the participating hospitals, health departments and universities will also be conducted to ascertain their expectations and requirements for the consent process. Specific Aim 2: Based on the data collected in Aim 1, create a state-of-the-art electronic informed consent information (EICI) tool for use in the clinical setting about the retention and use of residual biospecimens. The award-winning Genetic Science Learning Center will develop the professional EICI in Spanish and English. Validation of the EICI will be completed using feedback from both community and scientific advisory boards for the Michigan BioTrust. Specific Aim 3: Evaluate the EICI consent approach by comparing it to: a) traditional consent delivered on an electronic tablet; and b) the current paper-based consent approach. Both Spanish and English speaking parents (n = 630) in the state of Michigan, where informed consent is required for biobank research during postpartum clinical care, will be recruited and randomized to one of three groups. Specific Aim 4: Assess feasibility of the EICI through focus groups and interviews with birthing hospitals and Department of Community Health staff before and after the intervention.
For the intervention, a research assistant (RA) at each hospital, with permission of the healthcare professional, will ask potential participants if they are interested in participating in this study. If they are interested, the RAs will seek verbal consent for this study at this time. The RA will inform patients that when a healthcare provider comes into their room about the BioTrust, they will have the study information for them.
Then the RAs at the labor and deliver units of the hospitals will give an iPad to the healthcare providers seeking consent for the BioTrust. The healthcare providers will be blind to the study group assignment until they enter the patient's room. When a healthcare professional enters a patients' room, she will touch the iPad to see the study group assignment. Participants will be randomized to one of three study groups and this will be programmed automatically on the iPad. If they are in Group A or B, the healthcare providers will give the iPad to the patients to watch or read the consent information. If they are in Group C (control group) the standard brochure will be given about the BioTrust. Immediately following their decision, all participants will complete a brief knowledge survey on the iPad.
This recruitment approach mirrors the current clinical encounter for the BioTrust. This current approach is as follows. After newborn screening is completed, a healthcare professional approaches the mother in the hospital and provides them with the Michigan BioTrust brochure (see appendix) and then asks for the mother to consent to allow or not allow their infants' residual DBS to be stored in the Michigan BioTrust. This consent form is a simply check for yes and no with their signature and is attached to the back of the newborn screening card. For this study, after they receive the information in any of the study groups, all participants will still be required to sign this same consent form because it is attached to the physical sample of the newborn screening blood specimens.
All participating women will complete a survey 1) immediately following the intervention/control on the electronic table (Time 1) and 2) also will be surveyed by telephone 2-4 weeks follow up (Time 2).
Drs. Rothwell, Johnson and Tarini will provide guidance for the coordination of the clinical sites, due to their extensive experience. To ensure success there will be at least weekly communication between the sites and the Project Director, Dr. Johnson and monthly among the site personnel. Drs. Botkin, Rothwell and Johnson will visit each site prior to implementation of data collection to introduce the project and discuss issues sites may have. Once the RAs have been hired at each site they will provide weekly reports of activities and recruitment to the Research team in Utah. Monthly a teleconference will be held and the Site PI's will report on activities and recruitment to the Utah research team and the other site PI. Consistency among the sites will be monitored with these reports and communication strategies. Research team coordination with communication and meetings is based on the successful accomplishment of previous research project (R01 HD058854).
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention | Active Comparator | The EICI intervention group will receive an electronic interactive tool with movie clips and external links available through the tool. The movie intervention group will watch the educational consent movie and receive the standard paper-based brochure. |
|
| Control | Placebo Comparator | This group will receive the standard of care currently used (paper-based brochure) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| EICI Movie | Behavioral | The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by watching a brief video. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Comprehension for Biobanking at Time of Consent | Questions based on the 16-item biobank checklist developed from consensus-based guidelines for adequate comprehension for biobanking (see Beskow et al. 2014). This measure assesses a person's understanding of the Michigan BioTrust program. Scale range: 0-1 The reported scale is derived from the number of correct answers divided by 20 for a percentage correct. Thus, a score of .6 indicates a 60% correct response rate. Higher values indicate more comprehension of the presented information. Lower values indicate less comprehension of the presented information. | Administered immediately after the intervention |
| Measure | Description | Time Frame |
|---|---|---|
| Quality of Informed Consent | The Quality of Informed Consent assesses how well the participant self-reports their understanding different aspects of the study he/she consented into (Joffe et al., 2001). Scores range from 1 to 5 with higher scores indicating better self-reported understanding of the elements of consent. The scale is created by taking the mean of 14 items. | Administered immediately after the intervention |
Not provided
Inclusion criteria
Exclusion criteria
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Erin Rothwell, PhD | University of Utah | Principal Investigator |
| Jeffrey Botkin, MD | University of Utah | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Michigan Department of Health & Human Services | Lansing | Michigan | 48913 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 11734235 | Background | Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC. Quality of informed consent in cancer clinical trials: a cross-sectional survey. Lancet. 2001 Nov 24;358(9295):1772-7. doi: 10.1016/S0140-6736(01)06805-2. | |
| 25144889 | Background | Beskow LM, Dombeck CB, Thompson CP, Watson-Ormond JK, Weinfurt KP. Informed consent for biobanking: consensus-based guidelines for adequate comprehension. Genet Med. 2015 Mar;17(3):226-33. doi: 10.1038/gim.2014.102. Epub 2014 Aug 21. |
Not provided
Not provided
Individual data regarding knowledge about retention of newborn screening dried bloodspots is not useful data
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Intervention | The EICI intervention group will receive an electronic interactive tool with movie clips and external links available through the tool. The movie intervention group will watch the educational consent movie and receive the standard paper-based brochure. EICI Movie: The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by watching a brief video. EICI App: The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by exploring an educational app. |
| FG001 | Control | This group will receive the standard of care currently used (paper-based brochure) Control: Standard of care, paper-based brochure |
| Title | Milestones | Reasons Not Completed | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| In-Hospital |
|
| |||||||||||||||||||||
| Follow-Up |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Intervention | The EICI intervention group will receive an electronic interactive tool with movie clips and external links available through the tool. The movie intervention group will watch the educational consent movie and receive the standard paper-based brochure. EICI Movie: The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by watching a brief video. EICI App: The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by exploring an educational app. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Comprehension for Biobanking at Time of Consent | Questions based on the 16-item biobank checklist developed from consensus-based guidelines for adequate comprehension for biobanking (see Beskow et al. 2014). This measure assesses a person's understanding of the Michigan BioTrust program. Scale range: 0-1 The reported scale is derived from the number of correct answers divided by 20 for a percentage correct. Thus, a score of .6 indicates a 60% correct response rate. Higher values indicate more comprehension of the presented information. Lower values indicate less comprehension of the presented information. | The analysis population differs from the number of participants enrolled because the initial 15 to 20 participants at each hospital were considered to be run-in participants during which the protocol was evaluated for its effectiveness at that site and adjusted as needed. Our analysis plan was written to exclude these run-in participants. | Posted | Mean | Standard Deviation | score on a scale | Administered immediately after the intervention |
|
3 months
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Intervention | The EICI intervention group will receive an electronic interactive tool with movie clips and external links available through the tool. The movie intervention group will watch the educational consent movie and receive the standard paper-based brochure. EICI Movie: The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by watching a brief video. EICI App: The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by exploring an educational app. |
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Dr. Bob Wong | University of Utah | 801-587-9666 | bob.wong@nurs.utah.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Mar 6, 2018 | Apr 4, 2019 | Prot_SAP_000.pdf |
Not provided
Not provided
Not provided
Not provided
Not provided
| EICI App | Behavioral | The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by exploring an educational app. |
|
| Control | Behavioral | Standard of care, paper-based brochure |
|
| Attitudes Survey | Assesses support of the Michigan BioTrust program. This is a single item assessment. Full scale range is 1 to 4. Higher values indicate more support of the Michigan BioTrust. The scale is a likert scale: 1 = Not supportive at all, 4 = Very supportive | Administered at the 2-4 week follow-up |
| Residual Comprehension for Biobanking | This is a repetition of the Comprehension for Biobanking survey assessed immediately after the intervention. The residual Comprehension for Biobanking survey assesses a person's retention of knowledge of the Michigan BioTrust program two to 4 weeks after the intervention. Scale range: 0-1 The reported scale is derived from the number of correct answers divided by 20 for a percentage correct. Thus, a score of .6 indicates a 60% correct response rate. Higher values indicate more comprehension of the presented information. Lower values indicate less comprehension of the presented information. | Administered at the 2-4 week follow-up |
| Residual Quality of Informed Consent | Assessment of how well the participant understood different aspects of the study after a gap in time. The Residual Quality of Informed Consent is a repetition of the Quality of Informed Consent measure, now provided 2-4 weeks after the intervention. This measure assesses how well the participant self-reports their understanding different aspects of the study he/she consented into (Joffe et al., 2001). Scores range from 1 to 5 with higher scores indicating better self-reported understanding of the elements of consent. The scale is created by taking the mean of 14 items. | Administered at the 2-4 week follow-up |
| Residual Decisional Regret | The Residual Decisional Regret measure assesses a person's feelings of regret after making a decision (in this specific case, participation in the Michigan BioTrust). Scores range from 1 to 5 with lower values indicating better outcomes due to less regret. The scale is created by taking the mean of 5 items. | Administered at the 2-4 week follow-up |
| 7898294 | Background | O'Connor AM. Validation of a decisional conflict scale. Med Decis Making. 1995 Jan-Mar;15(1):25-30. doi: 10.1177/0272989X9501500105. |
| 32242760 | Derived | Rothwell E, Johnson E, Wong B, Goldenberg A, Tarini BA, Riches N, Stark LA, Pries C, Langbo C, Langen E, Botkin J. Comparison of Video, App, and Standard Consent Processes on Decision-Making for Biospecimen Research: A Randomized Controlled Trial. J Empir Res Hum Res Ethics. 2020 Oct;15(4):252-260. doi: 10.1177/1556264620913455. Epub 2020 Apr 3. |
| NOT COMPLETED |
|
|
| BG001 | Control | This group will receive the standard of care currently used (paper-based brochure) Control: Standard of care, paper-based brochure |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
| OG000 |
| Intervention |
The EICI intervention group will receive an electronic interactive tool with movie clips and external links available through the tool. The movie intervention group will watch the educational consent movie and receive the standard paper-based brochure. EICI Movie: The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by watching a brief video. EICI App: The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by exploring an educational app. |
| OG001 | Control | This group will receive the standard of care currently used (paper-based brochure) Control: Standard of care, paper-based brochure |
|
|
|
| Secondary | Quality of Informed Consent | The Quality of Informed Consent assesses how well the participant self-reports their understanding different aspects of the study he/she consented into (Joffe et al., 2001). Scores range from 1 to 5 with higher scores indicating better self-reported understanding of the elements of consent. The scale is created by taking the mean of 14 items. | The analysis population differs from the number of participants enrolled because the initial 15 to 20 participants at each hospital were considered to be run-in participants during which the protocol was evaluated for its effectiveness at that site and adjusted as needed. Our analysis plan was written to exclude these run-in participants. | Posted | Mean | Standard Deviation | score on a scale | Administered immediately after the intervention |
|
|
|
|
| Secondary | Attitudes Survey | Assesses support of the Michigan BioTrust program. This is a single item assessment. Full scale range is 1 to 4. Higher values indicate more support of the Michigan BioTrust. The scale is a likert scale: 1 = Not supportive at all, 4 = Very supportive | The number of participants analyzed does not match the numbers in the participant flow due to missing data at the question level. Participants were not required to answer every single question on the survey. | Posted | Mean | Standard Deviation | score on a scale | Administered at the 2-4 week follow-up |
|
|
|
|
| Secondary | Residual Comprehension for Biobanking | This is a repetition of the Comprehension for Biobanking survey assessed immediately after the intervention. The residual Comprehension for Biobanking survey assesses a person's retention of knowledge of the Michigan BioTrust program two to 4 weeks after the intervention. Scale range: 0-1 The reported scale is derived from the number of correct answers divided by 20 for a percentage correct. Thus, a score of .6 indicates a 60% correct response rate. Higher values indicate more comprehension of the presented information. Lower values indicate less comprehension of the presented information. | The number of participants analyzed does not match the numbers in the participant flow due to missing data at the question level. Participants were not required to answer every single question on the survey. | Posted | Mean | Standard Deviation | score on a scale | Administered at the 2-4 week follow-up |
|
|
|
|
| Secondary | Residual Quality of Informed Consent | Assessment of how well the participant understood different aspects of the study after a gap in time. The Residual Quality of Informed Consent is a repetition of the Quality of Informed Consent measure, now provided 2-4 weeks after the intervention. This measure assesses how well the participant self-reports their understanding different aspects of the study he/she consented into (Joffe et al., 2001). Scores range from 1 to 5 with higher scores indicating better self-reported understanding of the elements of consent. The scale is created by taking the mean of 14 items. | The number of participants analyzed does not match the numbers in the participant flow due to missing data at the question level. Participants were not required to answer every single question on the survey. | Posted | Mean | Standard Deviation | score on a scale | Administered at the 2-4 week follow-up |
|
|
|
|
| Secondary | Residual Decisional Regret | The Residual Decisional Regret measure assesses a person's feelings of regret after making a decision (in this specific case, participation in the Michigan BioTrust). Scores range from 1 to 5 with lower values indicating better outcomes due to less regret. The scale is created by taking the mean of 5 items. | The number of participants analyzed does not match the numbers in the participant flow due to missing data at the question level. Participants were not required to answer every single question on the survey. | Posted | Mean | Standard Deviation | units on a scale | Administered at the 2-4 week follow-up |
|
|
|
|
| 0 |
| 471 |
| 0 |
| 471 |
| 0 |
| 471 |
| EG001 | Control | This group will receive the standard of care currently used (paper-based brochure) Control: Standard of care, paper-based brochure | 0 | 240 | 0 | 240 | 0 | 240 |
Not provided
Not provided